By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Jazz Pharmaceuticals 

Corporate Headquarters
Fourth Floor, Connaught House

One Burlington Road
Dublin    4  Ireland
Phone: 353-1-634-7800 Fax: 353-1-634-7850


Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a specialty biopharmaceutical company of over 875 employees focused on diverse portfolio of products and/or product candidates in the areas of sleep, hematology/oncology, pain and psychiatry.

Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has U.S. offices in Palo Alto, CA and Philadelphia, PA, and has offices in various other locations in Europe. The company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what they do to accomplish results by driving to achieve Jazz’s mission: to improve patients’ lives by identifying, developing and commercializing important specialty pharmaceutical products to address unmet patient needs, and operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence.

U.S. addresses:
3180 Porter Drive
Palo Alto, CA 94304

1818 Market Street
Philadelphia, PA 19103

Key Statistics

Ownership: Public

Web Site: Jazz Pharmaceuticals
Symbol: JAZZ


Company News
Jazz Pharmaceuticals (JAZZ) Signs Lease for Big Space in Palo Alto 1/13/2015 3:32:36 PM
Jazz Pharmaceuticals (JAZZ) To Present At J.P. Morgan Healthcare Conference On January 12 1/6/2015 8:37:11 AM
Jazz Pharmaceuticals (JAZZ) Receives FDA Approval For Intravenous Administration Of Erwinaze® (Asparaginase Erwinia Chrysanthemi) 12/22/2014 7:40:56 AM
Jazz Pharmaceuticals (JAZZ) Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe Hepatic Veno-Occlusive Disease 12/12/2014 7:36:03 AM
Jazz Pharmaceuticals (JAZZ) And Concert Pharmaceuticals, Inc. (CNCE) Provide JZP-386 Program Update 12/9/2014 11:16:49 AM
Jazz Pharmaceuticals (JAZZ) To Present New Analysis Of Defibrotide Data In Patients With Hepatic Veno-Occlusive Disease (VOD) At American Society of Hematology Annual Meeting 12/3/2014 11:44:14 AM
Jazz Pharmaceuticals (JAZZ) Announces First Patients Enrolled In Phase 3 Trial Of Xyrem (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy 12/3/2014 10:06:40 AM
Jazz Pharmaceuticals (JAZZ) Announces Participation in Two Investor Conferences 11/25/2014 10:28:35 AM
Jazz Pharmaceuticals plc (JAZZ) Announces Participation In Two Investor Conferences 11/7/2014 8:21:40 AM
Jazz Pharmaceuticals plc (JAZZ) Announces Third Quarter 2014 Financial Results And Updated Guidance 11/5/2014 7:44:40 AM